In the 9 years since the publication of our 2011 review of targeted treatment of thyroid cancer with multikinase inhibitors, much has changed in the landscape of this heterogeneous disease. New multikinase and selective inhibitor treatments for medullary thyroid cancer, radioiodine-refractory thyroid cancer and anaplastic thyroid cancer have completed trials and improved progression-free survival. Many physicians are concerned by dose-limiting adverse effects of these drugs and are wary to begin treatment in patients who are systemically well but have marked disease burden, which makes the timing of treatment initiation challenging. Published mechanistic data on tyrosine kinase inhibitors (TKIs) have helped guide our understanding of how to dose effectively with these drugs. A major goal in TKI therapy is to optimize inhibition of oncogenic kinase drivers while maintaining patient quality of life. Real-world data have now been published on how TKIs have fared outside the clinical trial environment. In this Review, we provide a summary of published data on the efficacy of TKIs in clinical practice, to provide clinicians with a more realistic view of how their patients will manage and respond to TKI therapy. Furthermore, we review the data on mechanisms of inhibition, outcomes and adverse effects of TKIs and provide an update on targeted treatment of thyroid cancer, focusing on optimizing the timing of treatment initiation.
Pivotal phase III trials of multikinase inhibitors in the past decade have provided new options for treatment of radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer.
Once metastatic disease develops, the driver mutation and the pathology of the tumour inform treatment options.
Multikinase inhibitors exist on a scale of specificity that often reflects their ability to inhibit VEGF. VEGF inhibition is largely responsible for the effects of tyrosine kinase inhibitors in the management of metastatic thyroid cancer.
Both static and dynamic predictors can assist in determining which patients will benefit most from tyrosine kinase inhibitor therapy.
Adverse effects should be managed aggressively to maximize the duration of oncogenic kinase driver inhibition.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Australian Institute of Health and Welfare. Cancer Incidence Projections: Australia, 2011–2020. Cancer Series no. 66 https://www.aihw.gov.au/getmedia/a79de4a1-49f5-4c93-bc59-4d181430aa69/14096.pdf.aspx?inline=true (2012).
UK Cancer Research. Thyroid Cancer Incidence. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/thyroid-cancer#heading-Zero (2015).
Pandeya, N. et al. Increasing thyroid cancer incidence in Queensland, Australia 1982–2008 – true increase or overdiagnosis? Clin. Endocrinol. 84, 257–264 (2015).
Gild, M. L. et al. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat. Rev. Endocrinol. 7, 617–24 (2011).
Haugen, B. R. et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1–133 (2016).
Mazzaferri, E. L. Management of low-risk differentiated thyroid cancer. Endocr. Pract. 13, 498–512 (2007).
Schlumberger, M. et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2, 356–358 (2014).
Accardo, G. et al. Genetics of medullary thyroid cancer: an overview. Int. J. Surg. 41, S2–S6 (2017).
Ricarte-Filho, J. C. et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69, 4885–4893 (2009).
Chakravarty, D. et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J. Clin. Invest. 121, 4700–4711 (2011).
Gild, M. L. et al. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr. Relat. Cancer 20, 659–667 (2013).
Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676–690 (2014).
Kelly, L. M. et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad. Sci. USA 111, 4233–4238 (2014).
Ritterhouse, L. L. et al. ROS1 rearrangement in thyroid cancer. Thyroid 26, 794–797 (2016).
Landa, I. et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052–1066 (2016).
Bullock, M. et al. TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas. Clin. Endocrinol. 85, 283–290 (2016).
Weinstein, I. B. Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297, 63–64 (2002).
Druker, B. J. et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).
O’Neill, C. J. et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery 148, 1139–1145 (2010); discussion 1145–1146 (2010).
Xing, M. et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 309, 1493–1501 (2013).
Molinaro, E. et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. Nat. Rev. Endocrinol. 13, 644–660 (2017).
Tiedje, V. F. J. Therapeutic breakthroughs in metastatic thyroid cancer. Nat. Rev. Endocrinol. 2, 77–78 (2020).
Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014).
Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015).
Gianoukakis, A. G. et al. Prolonged duration of response in lenvatinib responders with thyroid cancer. Endocr. Related Cancer 25, 699–704 (2018).
Pitoia, F. & Jerkovich, F. Selective use of sorafenib in the treatment of thyroid cancer. Drug Design Dev. Therapy 10, 1119–1131 (2016).
Brose, M. S. et al. A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 6088 (2018).
Brose, M. S. et al. A phase 3, randomized, double-blind, placebocontrolled study of cabozantinib in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after prior VEGFR-targeted therapy [abstract]. Thyroid 28, A195 (2018).
Brose, M. S. et al. Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol. 17, 1272–1282 (2016).
Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. New Engl. J. Med. 368, 623–632 (2013).
Dunn, L. A. et al. Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers. J. Clin. Endocrinol. Metab. 104, 1417–1428 (2019).
Rothenberg, S. M. et al. Redifferentiation of iodine-refractory BRAF V600e-mutant metastatic papillary thyroid cancer with dabrafenib. Clin. Cancer Res. 21, 1028–1035 (2015).
Subbiah, V. et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J. Clin. Oncol. 36, 7–13 (2018).
Ferrari, S. M. et al. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 9, S28–S42 (2020).
de Groot, J. W. et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr. Rev. 27, 535–560 (2006).
Wells, S. A. Jr. et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015).
Wells, S. A. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134–141 (2012).
Elisei, R. et al. Cabozantinib in progressive medullary thyroid cancer. J. Clin. Oncol. 31, 3639–3646 (2013).
Drilon, A. E. et al. A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 102 (2018).
Hu, M. et al. Clinical activity of selective RET inhibitor, BLU-667, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study [abstract]. Thyroid 28 (Suppl. 1), A170 (2018).
Taylor, M. H. et al. Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 6018 (2019).
Wirth, L. et al. Registrational results of LOXO-292 in patients with RET-altered thyroid cancers [abstract LBA93]. Ann. Oncol. 30, v933 (2019).
Wirth, L. J. et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N. Engl. J. Med. 383, 825–835 (2020).
Oh, H. S. et al. Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment: a Korean multicenter study. Thyroid 29, 1804–1810 (2019).
Berdelou, A. et al. Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice. Thyroid 28, 72–78 (2018).
Locati, L. D. et al. Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy. Eur. J. Cancer 118, 35–40 (2019).
Nervo, A. et al. Lenvatinib in advanced radioiodine-refractory thyroid cancer: a snapshot of real-life clinical practice. Anticancer Res. 38, 1643–1649 (2018).
Matrone, A. et al. Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: from the clinical trials to the real life. Best Pract. Res. Clin. Endocrinol. Metab. 31, 319–334 (2017).
Teo, Y. K. & Ishak, W. Lenvatinib, in treating advanced malignant thyroid tumours, real life experience from University Malaya Medical Centre [abstract P2-151]. Ann. Oncol. 30 (Suppl. 6), vi133 (2019).
Denaro, N. et al. Lenvatinib long-term responses in refractory thyroid cancer: our mono-institutional real-life experience with the multidisciplinary approach and review of literature. Oncology 97, 206–210 (2019).
Tsang, V. H. M. Management of treatment-related toxicities in advanced medullary thyroid cancer. Curr. Opin. Oncol. 31, 236–242 (2019).
Chougnet, C. N. et al. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort. Thyroid 25, 386–391 (2015).
Valerio, L. et al. Predictors of vandetanib response in the locally advanced or metastatic medullary thyroid cancer: a single center experience [abstract]. Eur. Thyroid J. 5 (Suppl. 1), 77 (2016).
Dadu, R. et al. Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: MD anderson cancer center off label experience. J. Clin. Endocrinol. Metab. 100, E77–E81 (2015).
Iyer, C. et al. Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28, 79–87 (2018).
Dacosta Byfield, S. A. et al. Real-world treatment patterns among patients initiating small molecule kinase inhibitor therapies for thyroid cancer in the United States. Adv. Ther. 36, 896–915 (2019).
Bible, K. C. et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol. 11, 962–972 (2010).
Carr, L. L. et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 16, 5260–5268 (2010).
Cohen, E. E. W. et al. A phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother. Pharmacol. 74, 1261–1270 (2014).
Dadu, R. et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J. Clin. Endocrinol. Metab. 99, 2086–2094 (2014).
Kim, S. Y. et al. SoLAT (sorafenib lenvatinib alternating treatment): a new treatment protocol with alternating sorafenib and lenvatinib for refractory thyroid cancer. BMC Cancer 18, 956 (2018).
Capdevila, J. et al. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC). Eur. J. Endocrinol. 177, 309–317 (2017).
Robinson, B. G. et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95, 2664–2671 (2010).
Krajewska, J. et al. A noninferiority trial of cabozantinib (C) comparing 60mg vs 140mg orally per day to evaluate the efficacy and safety in patients (pts) with progressive, metastatic medullary thyroid cancer (MTC) [abstract 1829TiP]. Ann. Oncol. 29 (Suppl. 8), viii647–viii648 (2018).
Hesselink, E. N. K. et al. Response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis. Eur. J. Endocrinol. 172, R215–R225 (2015).
Tappenden, P. et al. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Health Technol. Assess. 23, 1–144 (2019).
Wirth, L. J. et al. Clinical activity of LOXO-292, a highly selective RET inhibitor, in patients with retaltered thyroid cancers [abstract]. Thyroid 28 (Suppl. 1), A171 (2018).
Schlumberger, M. et al. A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer. Clin. Cancer Res. 22, 44–53 (2016).
Paschke, L. et al. Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials. Eur. Thyroid J. 7, 308–312 (2018).
Rao, S. N. & Cabanillas, M. E. Navigating systemic therapy in advanced thyroid carcinoma: from standard of care to personalized therapy and beyond. J. Endocr. Soc. 2, 1109–1130 (2018).
Cabanillas, M. E. & Takahashi, S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin. Oncol. 46, 57–64 (2019).
Bai, Y. et al. Risk of venous and arterial thromboembolic events associated with tyrosine kinase inhibitors in advanced thyroid cancer: a meta-analysis and systematic review. Oncotarget 10, 4205–4212 (2019).
Chae, Y. K. et al. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: A case report and review. Oncotarget 9, 28281–28289 (2018).
Blevins, D. P. et al. Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer. Thyroid 24, 918–922 (2014).
Haddad, R. I. et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine 56, 121–128 (2017).
Tahara, M. et al. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. Eur. J. Cancer 106, 61–68 (2019).
Hay, I. D. et al. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. Surgery 154, 1448–1454 (2013); discussion 1454–1455 (2013).
Brose, M. S. et al. Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocr. Relat. Cancer 24, 237–242 (2017).
Smit, J. W. A. et al. Second interim analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) in the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC): a subgroup analysis of European patients [abstract P2-07-135]. Eur. Thyroid J. 7 (Suppl. 1), 85 (2018).
Smit, J. et al. Baseline patient characteristics from RIFTOS: A global noninterventional study evaluating the use of multikinase inhibitors for treatment of asymptomatic differentiated thyroid cancer refractory to radioactive iodine (RIFTOS MKI) [abstract P3-06-07]. Eur. Thyroid J. 5 (Suppl. 1), 163 (2016).
Dadu, R. & Cabanillas, M. E. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions. Minerva Endocrinol. 37, 335–356 (2012).
Banugo, P. & Amoako, D. Prehabilitation. BJA Educ. 17, 401–405 (2017).
Silver, J. K. & Baima, J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity, increase cancer treatment options, and improve physical and psychological health outcomes. Am. J. Phys. Med. Rehabil. 92, 715–727 (2013).
Jacobson, M. C. The experience of head and neck cancer survivorship (including laryngectomy): an integrated biopsychosocial model. Curr. Opin. Support Palliat. Care 12, 65–73 (2018).
Villasenor, A. et al. Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL study. J. Cancer Surviv. 6, 398–406 (2012).
Robinson, B. et al. Characterization of tumor size changes over time from the phase 3 study of lenvatinib in thyroid cancer. J. Clin. Endocrinol. Metab. 101, 4103–4109 (2016).
Gild, M. L. et al. Clinical guidance for radioiodine refractory differentiated thyroid cancer. Clin. Endocrinol. 88, 529–537 (2018).
National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Thyroid Carcinoma 2015 http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf (2015).
Brose, M. S., Worden, F. P., Newbold, K. L., Guo, M. & Hurria, A. Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT trial. J. Clin. Oncol. 35, 2692–2699 (2017).
Montero-Conde, C. et al. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas. Cancer Res. 73, 1 (2013).
Wirth, L. J. et al. Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC) [abstract]. J. Clin. Oncol. 37 (Suppl. 15), 6081 (2019).
Sugino, K. et al. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients. Endocrine J. 65, 299–306 (2018).
Wirth, L. J. et al. Treatment-emergent hypertension and efficacy in the phase 3 study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT). Cancer 124, 2365–2372 (2018).
Suzuki, C. et al. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head Neck 41, 3023–3032 (2019).
Lee, E. K. et al. Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean multicenter retrospective study. Thyroid 29, 1811–1819 (2019).
Tahara, M. et al. Impact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC) [abstract 1862PD]. Ann. Oncol. 30 (Suppl. 5), v756 (2019).
Takeuchi, S. et al. Early prediction of lenvatinib treatment efficacy by using 18F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study. BMJ Open 8, e021001 (2018).
Paschke, R. et al. Prognostic and predictive factors correlated with treatment outcomes for radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) patients receiving sorafenib or placebo on the phase III decision trial [abstract]. Exp. Clin. Endocrinol. Diabetes https://doi.org/10.1055/s-0035-1547604 (2015).
Yarchoan, M. et al. Molecular predictors of response to sorafenib in patients with radioactive iodine-resistant advanced thyroid cancer [abstract]. J. Clin. Oncol. 32 (Suppl. 15), 6088 (2014).
Sherman, S. I. et al. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer 122, 3856–3864 (2016).
Lassalle, S. et al. MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib. Oncotarget 7, 30461–30478 (2016).
Marusyk, A., Almendro, V. & Polyak, K. Intra-tumour heterogeneity: a looking glass for cancer? Nat. Rev. Cancer 12, 323–334 (2012).
Chmielik, E. et al. Heterogeneity of thyroid cancer. Pathobiology 85, 117–129 (2018).
Ryder, M. et al. Increased density of tumor-associated macrophages is associated with decreased survival in advanced thyroid cancer. Endocr. Relat. Cancer 15, 1069–1074 (2008).
Ferrari, S. M. et al. Immune and inflammatory cells in thyroid cancer microenvironment. Int. J. Mol. Sci. 20, 4413 (2019).
Antonelli, A., Ferrari, S. M. & Fallahi, P. Current and future immunotherapies for thyroid cancer. Expert Rev. Anticancer Ther. 18, 149–159 (2018).
Joo, L. J. S. et al. RET kinase-regulated microrna-153-3p improves therapeutic efficacy in medullary thyroid carcinoma. Thyroid 29, 830–844 (2019).
Cabanillas, M. E. et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid 28, 945–951 (2018).
Wang, J. R. et al. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF(V600E)-mutated anaplastic thyroid carcinoma. Thyroid 29, 1036–1043 (2019).
Chan, T. A. et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 30, 44–56 (2019).
Kunstman, J. W. et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet 24, 2318–2329 (2015).
Khan, S. A. et al. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck 41, 1928–1934 (2019).
Schlumberger, M. et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann. Oncol. 28, 2813–2819 (2017).
M.L.G. acknowledges funding from the Royal Australian College of Physicians and a research scholarship from the AVANT Foundation.
B.G.R. has received an honorarium from Loxo Oncology, outside the period of the written review. B.G.R., R.C.-B. and V.T. report personal fees from Eisai, outside the submitted work. M.L.G. declares no competing interests.
Peer review information
Nature Reviews Endocrinology thanks M. Schlumberger and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Gild, M.L., Tsang, V.H.M., Clifton-Bligh, R.J. et al. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nat Rev Endocrinol 17, 225–234 (2021). https://doi.org/10.1038/s41574-020-00465-y